According to Zacks, “Alpha Tau Medical Ltd. is a medical device company. It focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha Tau Medical Ltd., formerly known as Healthcare Capital Corp., is based in JERUSALEM. “
Several other research firms have also weighed in on DRTS. Piper Sandler assumed coverage on shares of Alpha Tau Medical in a report on Friday, April 8th. They issued an overweight rating and a $19.00 target price on the stock. Citigroup initiated coverage on Alpha Tau Medical in a report on Monday, April 4th. They issued a buy rating and a $21.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on Alpha Tau Medical in a research note on Thursday, April 14th. They set an overweight rating and a $20.00 target price for the company.
About Alpha Tau Medical (Get Rating)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers.
- Get a free copy of the StockNews.com research report on Alpha Tau Medical (DRTS)
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
- O’Reilly Automotive Hits A Pothole
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.